Intended Audience:
This course is designed for primary care physicians, psychiatrists, neurologists, geriatricians, geropsychiatrists, women’s health specialists, nurse practitioners, nurses, and related healthcare providers.

Registration:
Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:
Supported by an independent educational grant from Forest Pharmaceuticals, Inc.

Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials


Faculty Disclosures:

Mark H. Pollack, MD
Grant/Research Support: BMS, Cephalon, Forest, GSK, Janssen, Lilly, NARSAD, NIDA NIMH, Pfizer, Sepracor, UCB Pharma, Wyeth
Consultant: AstraZeneca, Brain Cells Inc., BMS, Cephalon, Forest, GSK, Janssen, Jazz Pharmaceuticals, Lilly, Medavante, Neurocrine, Novartis, Otsuka Pharmaceuticals, Pfizer, Predix, Roche, Sanofi, Sepracor, UCB Pharma, Wyeth|
Speaker’s Bureau: BMS, Forest, GSK, Janssen, Lilly, Pfizer, Solvay, Wyeth
Equity: Medavante

Gus Alva, MD
Grant/Research Support: Myriad, Corcept, Takeda, BMS/Otsuka, Forest, Wyeth, Novartis, Janssen, Pfizer

George T. Grossberg, MD
Grant/Research Support: Abbott, Forest, BMSQ, Janssen, Glaxo SKB, Lilly, Novartis, Pfizer, Wyeth, Eunoe
Consultant: BMSQ, Forest, Janssen, Novartis, Wyeth, Sanofi-Aventis, Glaxo SKB, Organon, Sepracor

Kevin Gray, MD
Speaker’s Bureau: Pfizer, Lilly, Forest, Novartis


Program Faculty:
Gus Alva, MD
Medical Director
ATP Clinical Research
Costa Mesa, CA

Kevin Gray, MD
Director, Geriatric Neuropsychiatry Clinic
Dallas Veteran Affairs Medical Center
Associate Professor of Psychiatry and Neurology
University of Texas Southwestern Medical Center
Dallas, TX

George T. Grossberg, MD
Samuel W. Fordyce Professor,
Department of Psychiatry
Director, Geriatric Psychiatry
St. Louis University School of Medicine
St. Louis University Hospital
St. Louis, MO

Mark H. Pollack, MD
Director, Center for Anxiety & Traumatic Stress Disorders
Massachusetts General Hospital
Associate Professor
Harvard Medical School
Boston, MA

Educational Objectives:

•Recognize the clinical, behavioral, physiological, and psychiatric signs and symptoms of individuals suffering from mild, moderate and severe depression, MDD, and generalized anxiety disorder.

•Recognize and manage the special challenges posed by patients with mixed neuropsychiatric disorders, including depression, AD, and GAD.

•Evaluate and compare the efficacy and safety features of pharmacologic agents used to treat depression, GAD, and mixed neuropsychiatric disorders.

•Implement and participate in multimodal approaches—counseling, pharmacological, support groups, and other resources—in order to provide comprehensive management of depression, AD, and generalized anxiety disorder in a wide range of patient populations, including women, men, and the elderly.

•Asses triggers for initiation of pharmacologic agents and stage patients with AD.

•Recognize early stage AD treatment triggers and use diverse modalities to confirm the diagnosis of AD.

•Categorize and implement approaches to achieve optimal reduction of adverse drug-related events in patients with AD, depression, GAD, and related conditions.